Skin Diseases, Infectious  >>  Cubicin (daptomycin)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cubicin (daptomycin) / Merck (MSD)
NCT00430937: Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections

Terminated
3
194
Europe
Daptomycin, Cubicin, Vancomycin, Vancocin, Teicoplanin, Targocid
Novartis Pharmaceuticals
Skin Diseases, Infectious, Soft Tissue Infections
03/08
 
NCT00772447: China Registration Study in Patients With Skin Infections

Completed
3
265
RoW
Daptomycin, Cubicin®, Vancomycin
AstraZeneca
Skin Diseases, Infectious
09/10
09/10
NCT01184872 / 2009-014391-22: Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections

Completed
3
120
Europe, RoW
Daptomycin, Vancomycin or Semi-Synthetic Penicillins (SSPs), Oxacillin,, Cloxacillin,, Flucloxacillin,
Novartis Pharmaceuticals
Infections
03/11
03/11

Download Options